Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wallentin, L.
PubMed
Right arrow Articles by Wallentin, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Emerging issues and new pharmacologic options for P2Y12 inhibition in acute coronary syndromes

The first 10% of the full text of this article appears below.

It is with great pleasure that we are able to provide you with the proceedings from the Special Symposium ‘Emerging issues and new pharmacologic options for P2Y12 inhibition in acute coronary syndromes’, presented at the International Society of Thrombosis and Haemostasis (ISTH) XXIst Congress, 2007. Both the symposium and this supplement were made possible by an . . . [Full Text of this Article]

Lars Wallentin

Uppsala Clinical Research Centre
Uppsala University, Uppsala
Sweden


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?